



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/415176/2024

European Medicines Agency decision P/0344/2024

of 13 September 2024

on the granting of a product specific waiver for tafasitamab (Minjuvi), (EMA-002499-PIP03-24) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Only the English text is authentic.



European Medicines Agency decision

P/0344/2024

of 13 September 2024

on the granting of a product specific waiver for tafasitamab (Minjuvi), (EMA-002499-PIP03-24) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the application submitted by Incyte Biosciences Distribution B.V. on 29 April 2024 under Article 13 of Regulation (EC) No 1901/2006,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 26 July 2024 in accordance with Article 13 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee has given an opinion on the granting of a product specific waiver.
- (2) It is therefore appropriate to adopt a decision granting a waiver.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

A waiver for tafasitamab (Minjuvi), powder for concentrate for solution for infusion, intravenous use the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

Article 2

This decision is addressed to Incyte Biosciences Distribution B.V, Paasheuvelweg 25, 1105 BP – Amsterdam, The Netherlands.

EMA/PDCO/237905/2024
Amsterdam, 26 July 2024

Opinion of the Paediatric Committee on the granting of a product-specific waiver

EMA-002499-PIP03-24

Scope of the application

Active substance(s):

Tafasitamab

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of mature B-cell neoplasms excluding diffuse large B-cell lymphoma

Pharmaceutical form(s):

Powder for concentrate for solution for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Incyte Biosciences Distribution B.V.

Basis for opinion

Pursuant to Article 13 of Regulation (EC) No 1901/2006 as amended, Incyte Biosciences Distribution B.V. submitted to the European Medicines Agency on 29 April 2024 an application for a product-specific waiver on the grounds set out in Article 11 of said Regulation for the above mentioned medicinal product.

The procedure started on 27 May 2024.

Opinion

1. The Paediatric Committee, having assessed the waiver application in accordance with Article 13 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to grant a product-specific waiver for all subsets of the paediatric population and the above mentioned condition(s) in accordance with Article 11(1)(c) of said Regulation, on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments for paediatric patients.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The grounds for the granting of the waiver are set out in Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

Grounds for the granting of the waiver

1. Waiver

1.1. Condition:

Treatment of mature B-cell neoplasms excluding diffuse large B-cell lymphoma

The waiver applies to:

- all subsets of the paediatric population from birth to less than 18 years of age;
- powder for concentrate for solution for infusion, intravenous use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

Condition(s) and authorised indication(s)

1. Diffuse large B-cell lymphoma

Authorised indication(s):

- MINJUVI is indicated in combination with lenalidomide followed by MINJUVI monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).
 - Invented name(s): MINJUVI
 - Authorised pharmaceutical form(s): powder for concentrate for solution for infusion
 - Authorised route(s) of administration: intravenous use
 - Authorised via centralised procedure